The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

Press Releases Subscribe to our News

17 May 2024

Regulatory

Notice of annual general meeting in Biosergen AB

Release
10 May 2024

Regulatory

Biosergen publishes 2023 annual report

Release
16 April 2024

Regulatory

Conversion of paid subscribed units and first day of trading with warrants of series TO3

Release
09 April 2024

Regulatory

Biosergen resolves on a directed issue to underwriters in connection with the completed rights issue

Release
26 March 2024

Regulatory

Biosergen announces the outcome in the rights issue

Release
15 March 2024

Regulatory

Members of the board of directors and management subscribe in ongoing rights issue

Release
05 March 2024

Regulatory

Biosergen publishes prospectus due to rights issue of units

Release
01 March 2024

Regulatory

Bulletin from the extraordinary general meeting in Biosergen AB (publ)

Release
29 February 2024

Regulatory

Biosergen publishes interim report for fourth quarter 2023

Release
Q4-2023 Financial Report
12 February 2024

Regulatory

Biosergen receives regulatory approval to test lead candidate BSG005 in patients with invasive fungal infection.

Release
30 January 2024

Regulatory

Notice of Extraordinary general meeting in Biosergen AB

Release

Regulatory

Biosergen carries out a rights issue of units of approximately SEK 40.5 million, and secures bridge loan

Release
12 January 2024

Regulatory

Biosergen Announces Leadership Transition: Peder M. Andersen to Step Down as CEO, Tine Olesen Appointed as Successor

Release
12 December 2023

Regulatory

Biosergen’s Partner Alkem Laboratories Submits Clinical Trial Application for First Patient Study with BSG005 in Invasive Fungal Infections in India as a Rescue Therapy

Release
30 November 2023

Regulatory

Biosergen publishes interim report for third quarter 2023

Release
Q3-2023 Financial Report

Regulatory

Biosergen AB changes Certified Adviser to Carnegie Investment Bank AB (publ)

Release
25 September 2023

Regulatory

Biosergen and Alkem Laboratories Ltd collaborates to develop anti-infective for severe fungal infections

Release
28 August 2023

Regulatory

Warrants series TO2 were exercised to approximately 96.1 percent and Biosergen AB receives approximately SEK 5.5 million

Release
22 August 2023

Regulatory

The last day of trading in warrants series TO2 in Biosergen AB is today, August 22, 2023

Release
16 August 2023

Regulatory

Biosergen Receives Full Subscription Guarantees for Warrant Exercise from Largest Shareholders and Executive Management

Release
14 August 2023

Regulatory

Biosergen publishes interim report for first quarter 2023

Release
Q2-2023 Financial Report
11 August 2023

Regulatory

The subscription price for warrants series TO2 in Biosergen has been determined to SEK 0.66 and the exercise period starts on August 14, 2023

Release

Regulatory

Biosergen publish financial report for second quarter ahead of schedule.

Release
07 August 2023

Regulatory

Biosergen Announces Abstract Accepted for Presentation at the 11th Congress on Trends in Medical Mycology (TIMM-11)

Release
31 May 2023

Regulatory

Biosergen publishes interim report for first quarter 2023

Release
Q1-2023 Financial Report

Regulatory

Bulletin from the annual general meeting on 31 May 2023 in Biosergen AB

Release
10 May 2023

Regulatory

Biosergen publishes 2022 annual report

Release
28 April 2023

Regulatory

Notice of annual general meeting in Biosergen AB

Release
31 March 2023

Regulatory

Biosergen publishes interim report for fourth quarter 2022

Release
Q4-2022 Financial Report
29 March 2023

Regulatory

Biosergen provides Phase 2 clinical development strategy update

Release
30 November 2022

Regulatory

Biosergen publishes interim report for third quarter 2022

Release
Q3-2022 Financial Report
04 October 2022

Regulatory

Biosergen announces the outcome in the rights issue

Release
08 September 2022

Regulatory

Biosergen moves into the MAD (Multiple Ascending Dose) part of its phase I study after 4 cohorts tested in the SAD (Single Ascending Dose) part of the study.

Release
02 September 2022

Regulatory

Biosergen AB: Biosergen’s Board of Directors decides on a rights issue of units of approximately SEK 60.2 million

Release
31 August 2022

Regulatory

Biosergen publishes interim report for second quarter 2022

Release
Q2-2022 Financial Report

Regulatory

Biosergen receives a loan of SEK 7 million to finance continued development

Release
26 August 2022

Regulatory

Biosergen completes the third cohort of BSG005 phase I trial

Release
30 June 2022

Regulatory

Biosergen successfully completes second cohort of BSG005 phase I trial

Release
28 June 2022

Regulatory

Announcement from the annual general meeting held on June 28, 2022 in Biosergen AB

Release
07 June 2022

Regulatory

Biosergen publishes 2021 Annual report

Release
31 May 2022

Regulatory

Biosergen publishes interim report for first quarter 2022

Release
2022-Q1 Financial Report
13 May 2022

Regulatory

Biosergen successfully completes first cohort of BSG005 phase I trial

Release
07 April 2022

Regulatory

The first subject has been dosed in the phase I trial of BSG005

Release
31 March 2022

Regulatory

Biosergen publishes interim report for fourth quarter 2021

Biosergen Q4 financial report press release
Q4-2021 Financial Report
30 November 2021

Regulatory

Biosergen publishes interim report for the third quarter 2021

Q3-2021 Financial Report
Biosergen Q3 financial report press release
31 August 2021

Regulatory

Biosergen publishes interim report for the second quarter 2021

Q2-2021 Financial Report
Biosergen Q2 report press release
27 June 2021

Regulatory

Biosergen’s groundbreaking antifugal drug BSG005 is granted Orphan Drug status in the United States

Release
08 June 2021

Regulatory

BIOSERGEN’S OFFERING IS FULLY SUBSCRIBED

Biosergens offering fully subscribed